Navigation Links
TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
Date:10/1/2008

ther indications, the potential for NGX426 to be analgesic, the anticipated timing of results for the NGX426 study in a model of capsaicin-induced pain, the potential for NGX267 as a treatment for xerostomia secondary to Sjogren's syndrome, the anticipated timing of results from the study of NGX267 as a treatment for xerostomia secondary to Sjogren's syndrome, and the ability to partner any of the company's product candidates or programs. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of the company's product candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of the company's product candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of the company's product candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's product development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel or NGX426 will successfully treat migraine and/or other indications for which they are developed, that NGX267 will successfully
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. TorreyPines Therapeutics Reports Third Quarter 2007 Results
7. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Researchers have pioneered ... images. The new technology, called Virtual Finger, allows ... structures like neurons and synapses using the flat ... technology makes 3D imaging studies orders of magnitude ... an unprecedented level across many areas of experimental ...
(Date:7/10/2014)... Cleveland, Ohio (PRWEB) July 10, 2014 ... in ion channel-expressing cell lines, and the gap that ... new cells that expand its industry-leading portfolio of validated ... focuses on ion channel-expressing cell lines, as ion channels ... able to control this activity creates the potential to ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been upgraded ... with a second treatment cup to help prevent and smooth ... is thinner on the edges for a softer contact with ... uneven surfaces on the face, neck and décolleté. Choose to ... areas such as the cheeks and neck, or opt for ...
(Date:7/10/2014)... July 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, ... today announced an agreement with Lineagen, Inc., ... Lineagen,s NextStep Dx PLUS.  Lineagen, focused ... neurological disorders, currently offers FirstStep Dx ... service used by healthcare providers as a ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... Commencement of Longer-term Phase 2 Switching Study, ... Therapeutics, a,biopharmaceutical company developing small-molecule, orally administered,pharmacological ... diseases,announced today that the Company will present ... of Plicera(TM) (isofagomine tartrate) for Gaucher disease,at ...
... of smaller and faster, the next breakthroughs in the ... and data storage devices created out of novel materials ... techniques and new ways to position the molecules, NIST ... Physical Society how they have improved manipulation of so-called ...
... 12 Barr,Pharmaceuticals, Inc. (NYSE: BRL ) ... has received final approval from the U.S. Food ... Bristol-Myers Squibb,Company,s Taxol(R) (paclitaxel) Injection USP, 6mg/mL, packaged ... Company plans to,launch its product shortly. Barr,s U.S. ...
Cached Biology Technology:Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease 2Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease 3Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease 4Copolymers block out new approaches to microelectronics at NIST 2Barr Receives Approval for Generic Taxol(R) Injection USP, 6mg/mL 2Barr Receives Approval for Generic Taxol(R) Injection USP, 6mg/mL 3
(Date:7/10/2014)... 30, 2014  Aware, Inc. (NASDAQ: AWRE ... previously announced on June 26, 2014 that its Board ... $1.75 per share, or approximately $40 million in total.  ... 2014 and a payment date of July 24, 2014.  ... had set an ex-dividend date for this special cash ...
(Date:7/10/2014)... July 3, 2014 According to ... Type (Swipe And Area), Material (Optical Prism, Pizeoelectric, Capacitive, ... Security and Banking & Finance), and Geography - Global ... MarketsandMarkets, the global Fingerprint Sensors Market is projected to ... CAGR of 16.8% from 2014 to 2020. ...
(Date:7/10/2014)... 2014  Acuity Market Intelligence today released forecasts from "The ... that the global market for National Electronic ID (eID) programs ... During this time, the number of National eID cards in ... Asia , with its vast population, will dominate ... issued, while Europe trails a distant ...
Breaking Biology News(10 mins):NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3National Electronic ID Programs Generate $54 Billion Between 2013 and 2018 with 3.5 Billion National eID Card Holders Worldwide 2
... Belgium, Copenhagen, Denmark, and Shenzhen, China -- ICG Europe ... on June 28 in Ghent, Belgium presenting numerous recent ... spectrum of genomics topics have been discussed in greater ... research, plant and animal genomics, and metagenomics. ...
... the day. They are coordinated by a central clock ... virtually every cell. Many molecular gearwheels of this internal ... the Faculty of Science of the University of Geneva ... subordinate oscillators, the researcher,s group used a variety of ...
... are a lot of small molecules people would like ... something useful, according to University of Wisconsin-Madison chemist Robert ... most responsible for far-reaching effects on global climate. Nitrogen ... into the valuable agricultural fertilizer ammonia. Plants perform the ...
Cached Biology News:Genomes for science, genomes for life, and genomes for you and me 2Genomes for science, genomes for life, and genomes for you and me 3Genomes for science, genomes for life, and genomes for you and me 4Genomes for science, genomes for life, and genomes for you and me 5Observing live gene expression in the body 2Diamond catalyst shows promise in breaching age-old barrier 2
12 breakable polypropylene strips of 8 wells each held in a rigid frame. Ideal for antibody assays....
... Human IgM Assay Kit to address the ... assay for Human IgM that eliminates the ... a simple mix-and-read assay that allows the ... ng/ml in approximately 30 minutes. The Pierce ...
... adsorption and clarification reagent; Ideal for ... of antibodies, proteins, nucleic acids, & ... cross-reactivity, and improves downstream processing; Utilizes ... non-ionic adsorbent supplied as a suspension ...
A simple, sensitive and reliable method for determining free sulfhydryl content in peptides, protein...
Biology Products: